Spatially resolved enzyme-linked assay

• US 20040038241A1
• Filed: 08/04/2003
• Published: 02/26/2004
• Est. Priority Date: 07/26/2000
• Status: Abandoned Application

• Current Assignee: ChemoMetec A/S
• Original Assignee: ChemoMetec A/S
• Inventors: Glennsbjerg, Martin
• Application Number:
  US10/333,734
• Publication Number:
  US 20040038241A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: G01N 33/536 with immune complex formed in liquid phase
• CPC Class Codes: G01N 33/56972 White blood cells

Abstract

The present invention relates to a method of assessing at least one quality parameter and/or at least one quantity parameter of at lest one analyte wherein said at least one analyte is connected to a catalyst capable of catalysing a substrate into a product, whereby the analyte is assessed through detection of product produced around the analyte. More particularly the present invention relates to a method of assessing at least one quality parameter or at least one quantity parameter of at least one species of analytes in a sample comprising the steps of establishing a sample domain having at least one wall, arranging in the sample domain catalyst-analyte complexes between the at lest one species of analytes and at least one catalyst in a manner allowing the analytes to move relative to the wall(s) of the sample domain, arranging a substrate in the sample domain, said substrate being capable of being converted into a product through catalysation by said catalyst, contacting the substrate with the catalyst-analyte complexes of individual analytes allowing a detectable amount of product to be produced, recording an image of the product related to individual analytes in the sample domain, correlating the image to the at least one quality parameter or the at least one quantity parameter of the at least one species of analytes.

Claims

1. A method for assessing at least one quality parameter or at least one quantity parameter of at least one species of analytes in a sample comprising the steps of

establishing a sample domain having at least one wall,

arranging catalyst-analyte complexes between the at least one species of analytes and at least one catalyst in a manner allowing the analytes to move relative to the wall(s) of the sample domain,

arranging a substrate in the sample domain, said substrate being capable of being converted into a product through catalysing by said catalyst,

contacting the substrate with the catalyst-analyte complexes of individual analytes allowing a detectable amount of product to be produced,

recording an image of the product related to individual analytes in the sample domain,

correlating the image to the at least one quality parameter or at least one quantity parameter of the at least one species of analytes.

2. The method according to claim 1, wherein the catalyst-analyte complex comprises a species-selective linkage.

3. The method according to claim 2, wherein the species-selective linkage comprises an antigen-antibody linkage.

4. The method according to claim 2, wherein the species-selective linkage comprises a DNA, or RNA, or PNA, or LNA hybridisation.

5. The method according to claim 1, wherein formation of the catalyst-analyte complex comprises catalysed reporter deposition.

6. The method according to claim 1, whereby analytes are particles, such as biological particles.

7. The method according to claim 1, wherein the analytes are bound to a solid support, preferably where such solid support are beads in suspension.

8. The method according to claim 1, whereby the analytes are selected from the group consisting of cells, cell walls, bacteria, plasmodia, virus, prions, macromolecules, proteins, polypeptides, peptides, genes, DNA, RNA, or fragments or clusters thereof.

9. The method according to claim 1, whereby the at least one species of analyte is a medical marker of a disease.

10. The method according to claim 9, whereby the marker is a marker for cardial infarct.

11. The method according to claim 8, wherein the cells are selected from mammalian cells, insect cells, reptile cells, fish cells, yeast cells, and fungi cells.

12. The method according to claim 8, wherein the cells are selected from blood cells, sperm cells, and bone marrow cells.

13. The method according to any of the preceding claims, whereby the sample is a liquid sample.

14. The method according to any of the preceding claims, whereby the sample is selected from the group consisting of milk, milk products, urine, blood, sperm, nasal secrete, tears, faeces, waste water, process water drinking water, cerebrospinal fluid, gall, bone marrow, food, feed, and mixtures, dilutions, or extracts thereof

15. The method according to any of claims 1-12, whereby the sample is a solid sample, which is pre-treated prior being arranged in the sample domain.

16. The method according to claim 15, whereby the sample is a biopsy of a muscle, a brain, a kidney, a liver, a spleen.

17. The method according to any of the preceding claims, whereby the substrate is AttoPhos, 4-MUP, HNPP, 4-MUG, CDP-Star, CSPD, Super Signal Substrate (Pierce, Rockford, Ill.), Luminol/4-iodophenol, Galacton Plus, DAB, OPD, AEC, 5AS, 2,2′

-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid), 4C1N, o-dianisidine, TMB, ABTS, BCIP, Naphthol AS-TR phosphat, pNPP, PMP, X-Gal, CPRG.

18. The method according to any of the preceding claims whereby the catalyst is an inorganic catalyst.

19. The method according to any of the claims 1-17, whereby the catalyst is an organic catalyst.

20. The method according to claim 19, whereby the catalyst is an enzyme.

21. The method according to claim 20, whereby the catalyst is selected from the group consisting of phosphatase such as alkaline phosphatase, O-galactosidase, peroxidase such as for example horseradish peroxidase, β

-glucuronidase, β

-glucose-6-phosphate dehydrogenase, glucose oxidase, urease, luciferase, β

-lactamase and β

-amylase.

22. The method according to any of the preceding claims, whereby at least one obtained product precipitates upon formation.

23. The method according to claim 22, whereby at least one obtained product precipitates on a surface of the sample compartment.

24. The method according to any of the preceding claims, whereby at least one obtained product is coloured.

25. The method according to any of the preceding claims, whereby at least one obtained product is photoluminescent or chemiluminescent.

26. The method according to any of the preceding claims, whereby at least one obtained product is fluorescent.

27. The method according to any of the preceding claims, whereby at least one obtained product emits electromagnetic radiation in the range of 300 nm to 1200 nm when exposed to electromagnetic radiation in the range of 250 nm to 600 nm.

28. The method according to any of the preceding claims, wherein at least one product obtained is excited by excitation light prior to recording an image.

29. The method according to claim 28, wherein the excitation light is a light source selected from the group of, light emitting diode (LED), gas laser, solid state laser, laser diode, gas lamp, halogen lamp, xenon lamp.

30. The method according to any of the preceding claims, whereby the sample domain is three-dimensional.

31. The method according to any of the preceding claims, whereby the sample domain is a flow through chamber.

32. The method according to any of the preceding claims, whereby the sample domain is part of a disposable cassette.

33. The method according to any of the preceding claims, whereby at least one wall of the sample domain is transparent.

34. The method according to any of the preceding claims, whereby at least one linkage between the catalyst and the analyte comprises two or more antibodies.

35. The method according to any of the preceding claims, whereby at least one catalyst is conjugated to an antibody being immunologically bound to an antigen on the species of analyte.

36. The method according to any of the preceding claims, whereby at least one catalyst is conjugated to a first antibody being immunologically bound to second antibody, being immunologically bound to an antigen on the species of analyte.

37. The method according to any of the preceding claims, whereby at least one catalyst is conjugated to avidin.

38. The method according to any of the preceding claims, whereby at least one catalyst is conjugated to streptavidin.

39. The method according to any of the preceding claims, whereby at least one linkage comprises a catalyst conjugated to avidin, an antibody conjugated to biotin and being immunologically bound to an antigen on the species of analyte or vice versa.

40. The method according to any of the preceding claims, whereby at least one linkage comprises a catalyst conjugated to avidin, a first antibody conjugated to biotin, and a second antibody being immunologically bound to an antigen on the species of analyte.

41. The method according to any of the preceding claims, whereby the linkage is formed before the sample is transferred to the sample domain.

42. The method according to any of the preceding claims, wherein the analyte is a DNA containing analyte and the DNA or fractions of the DNA are stained with a DNA staining compound.

43. The method according to any of the preceding claims, whereby an additional linkage is formed between a-second species of analyte and a second catalyst.

44. The method according to any of the preceding claims, whereby two or more additional linkages are formed between a second, third and optionally subsequent species of analyte and a second, third, and optionally third catalyst.

45. The method according to any of the preceding claims, further comprising the step of removing excess catalyst not being linked to the species of analytes.

46. The method according to claim 45, whereby excess catalyst is removed through centrifugation.

47. The method according to claim 45, whereby excess catalyst is removed through filtration.

48. The method according to claim 45, whereby excess catalyst is removed through flushing.

49. The method according to claim 45, whereby removal of excess catalyst comprises binding the analyte-catalyst complex to a magnetic bead.

50. The method according to any of the preceding claims, further comprising the contacting of co-factors with the catalyst-analyte complex.

51. The method according to any of the preceding claims, further comprising the contacting of a buffer with the catalyst-analyte complex.

52. The method according to any of the preceding claims, whereby at least one substrate is added to the catalyst-analyte complex in the sample domain.

53. The method according to any of the preceding claims, whereby at least one substrate is added to the catalyst-analyte complex before transferring it to the sample domain.

54. The method according to any of the preceding claims, whereby the initiation of the reaction catalysed by the catalyst is controlled by temperature changes.

55. The method according to any of the preceding claims, whereby a pre-substrate is added to the catalyst-analyte complex before transferring it to the sample domain.

56. The method according to claim 55, whereby a conversion of the pre-substrate into the substrate can be controlled externally.

57. The method according to claim 56, whereby the conversion is controlled by illumination.

58. The method according to claim 56, whereby the conversion is controlled by a change in temperature.

59. The method according to any of the preceding claims, whereby the reaction catalysed by the catalyst can be controllably stopped externally.

60. The method according to any of the preceding claims, whereby the step of producing a product is carried out in a liquid environment.

61. The method according to any of the claims 1-59, whereby the step of producing a product is carried out in a viscous environment.

62. The method according to any of the claims 1-59, whereby the step of producing a product is carried out in a semi-solid environment, preferably where the semisolid environment is a gel.

63. The method according to claim 62, wherein the semi-solid environment is formed after the analytes have been introduced to the sample compartment, preferably where the forming of the semi-solid environment is controlled by external factors such as temperature, light and agitation.

64. The method according to any of the preceding claims, whereby the duration of the step of producing a product is below 60 minutes.

65. The method according to claim 64, whereby the duration of the step of producing a product is below 15 minutes, preferably below 5 minutes, more preferably below 1 minute, more preferably below 30 seconds, more preferably below 15 seconds, more preferably below 10 seconds, more preferably below 5 seconds, more preferably below 2 seconds.

66. The method according to any of the preceding claims, whereby the recording of image comprises the use of a confocal scanner.

67. The method according to any of the preceding claims, whereby the image of product is recorded using an array of detection devices.

68. The method according to claim 67, wherein the image of product is recorded using a one-dimensional array of detection devices.

69. The method according to claim 67, wherein the image of product is recorded using a two-dimensional array of detection devices.

70. The method according to claim 67, wherein the image of product is recorded using a CCD, a CMOS, a video camera or a photon counting camera.

71. The method according to any of the preceding claims, whereby the image is recorded without magnification.

72. The method according to any of the preceding claims, whereby the image is recorded with a magnification factor below 20, preferably below 10, more preferably below 5, such as 4, more preferably below 4 such as 2, more preferably below 2 such as 1.

73. The method according to any of the preceding claims, whereby the image is recorded with a magnification factor below 1, preferably below 0.9, such as 0.8, more preferably below 0.8 such as 0.6, more preferably below 0.6 such as 0.5.

74. The method according to any of the preceding claims whereby the image is recorded in one exposure.

75. The method according to any of the claims 1-73 whereby the image is recorded in two, three or more exposures.

76. The method according to claim 75, wherein the assessment of at least one quality parameter or at least one quantity parameter is done by correlating more than one image to the at least one quality parameter or at least one quantity parameter, preferably by correlating two images, more preferably correlating more than two images, more preferably correlating more than four images.

77. The method according to claim 76, where information about the changes in the image in course of time is used in the assessment of at least one quality parameter or at least one quantity parameter.

78. The method according to any of the preceding claims, whereby the recorded image is processed.

79. The method according to claim 78, whereby the recorded image is processed using data processing means.

80. The method according to claim 79, whereby the data processing means distinguish partially overlapping areas of product.

81. The method according to any of the preceding claims, whereby the correlation comprises estimation of the number of spots on the image.

82. The method according to any of the preceding claims, whereby the correlation comprises estimation of the size of spots on the image.

83. The method according to any of the preceding claims, whereby the correlation comprises distinction between at least two spectral properties of product.

84. The method according to any of the preceding claims, further comprising the assessment of at least one additional quality parameter or at least one additional quantity parameter.

85. The method according to claim 84, whereby the assessment of the at least one additional quality parameter or at least one additional quantity parameter comprises detection of fluorescence, chemiluminescence, photoluminescence, autoluminescence of a species of analyte.

86. The method according to any of the preceding claims, whereby the at least one quality parameter is selected from the group consisting of viability, size, identity, respiration, and presence of an analyte.

87. The method according to any of the preceding claims, whereby the at least one quantity parameter is selected from the group consisting of number of species of analyte in a volume of sample, concentration of species of analyte in a volume of sample, amount of species of analyte in a volume of sample.

88. The method according to any of the preceding claims, whereby the recording of an image further comprises exposing a first surface of the sample directly with excitation light from a first light means having at least a first light source, by use of focusing means detecting a fluorescence signal from the first surface of the sample onto a first detection means comprising at least a first detector.

89. The method according to claim 88, wherein at least the first light means is located in a first light plane parallel to the sample plane, said first light plane being between the sample plane and the first detection means.

90. The method according to any of the preceding claims 88-89, wherein an excitation light filter is inserted in the excitation light path from at least one light source.

91. The method according to claim 89, wherein the excitation light is arranged as light sources on a supporting material.

92. The method according to any of the preceding claims 88-91, wherein substantially identical filters are used for all the light sources.

93. The method according to any of claims 88-92, wherein a first light source is filtered through a first filter, and a second light source is filtered through a second filter, the first filter and the second filter being different.

94. The method according to any of the preceding claims 88-93, further comprising exposing a second surface of the sample directly with excitation light from a second light means having at least one light source.

95. The method according to claim 94, wherein the second excitation light means is located in a second light plane said plane being parallel with the sample plane and located on the other side of the sample plane than the first light plane allowing the sample to be exposed on two opposite surfaces.

96. The method according to claim 94 or 95, wherein a filter inserted in the light path from the second light means is different from a filter inserted in the light path of the first light means.

97. The method according to any of claims 88-96, wherein a second detection means is arranged so that the sample compartment is positioned between the first detection means and the second detection means.

98. The method according to claim 97, wherein the first detection means is identical with the second detection means.

99. The method according to any of the preceding claims 88-98, wherein an emission light filter is inserted in the emission light path to at least the first detector.

The method according to any of the preceding claims 88-99, wherein a collimating lens is arranged in the emission light path.

100. The method according to any of the preceding claims 88-100, wherein the angle between the excitation main light and the detection-sample axis is in a range between 35°

and 90°

, preferably between 45° and

85°

, more preferably between 50° and

85°

.

101. The method according to claim 88, wherein at least the first light means is located in a first light plane parallel to the sample plane, said first light plane being positioned at a distance from the sample plane behind the detector.

102. The method according to claim 102, wherein the detector is positioned in a housing having an opening allowing the emitted signals to reach the detector(s).

103. A system for the assessment of at least one parameter of analytes in a liquid sample, comprising

a device comprising a sample domain comprising an exposing domain, an inlet through which a volume of a liquid sample representing the analyte material can been introduced, and a flow system comprising at least a channel allowing at least a portion of the volume of the liquid sample to flow within the device,

the device further comprising means to control the flow of liquid around a catalyst-analyte complex in the sample domain,

a detection device comprising at least a first detector for quantitatively detecting spatial image data and a processor for processing the detected image presentation,

the device and the detection device having means for arranging the device in relation to the detection device in a manner allowing electromagnetic signals from a sample in the exposing domain of the device to pass to the detection device and to form, in the detection device, a spatial image representation of the exposing domain.

104. A system according to claim 104, wherein the flow system additionally comprises a compartment or a flow channel part in or from which at least part of one or more reaction components initially loaded in the compartment or flow channel part is added to at least a portion of the volume of the liquid representing the sample.

105. A system according to claim 104, further comprising at least a first light source.

111. Use of a system according to claim 104-111 for diagnosis of a condition in an individual.

106. A system according to claim 106, wherein the first light source comprises an excitation light source.

109. The system according to claim 106 or 108, further comprising an excitation light filter inserted into the excitation light path.

107. A system according to claim 107, wherein the first light source and the detector are located on the same side of the exposing domain.

108. A system according to claim 108, comprising a second light source and a second detector, located on the opposite side from the first light source and first detection means.

110. The system according to claim 110, wherein the excitation light filter is essentially circular, such as essentially ring formed.

112. The use according to claim 112, wherein the individual is a human being.

113. The use according to claim 112, wherein the individual is an animal other than humans, such as cow, pig, horse, poultry, sheep, goat.

114. The use according to claim 112, wherein the condition is cardial infarct or a risk for suffering form a cardial infarct.